
|Articles|April 12, 2018
Ipsos Healthcare Releases Pan-Cancer Testing Monitor in Australia
Advertisement
Ipsos Healthcare-the global healthcare business of Ipsos-announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market.
The study gathers insights from medical oncologists and pathologists on topics such as awareness and current utilization of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
2
Marty Makary Out as FDA Commissioner: Report
3
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
4
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu
5




